Managing Hypercortisolism: Benefits and Risks of Cushing Syndrome Interventions

San Francisco, CA US
September 4, 2014

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with Cushing’s disease.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Recognize symptoms and apply current clinical guidelines in the diagnosis of Cushing syndrome
  • Discuss the pathophysiology of hypercortisolism
  • Discuss the current clinical research on the clinical impacts of subclinical Cushing syndrome
  • Assess available interventions and select appropriate therapy in the treatment and management of patients with Cushing syndrome
  • Discuss the role and recognize the benefits, risks and contraindication of glucocorticoid receptor blockade in the management of hyperglycemia associated with Cushing syndrome
  • Explain the role of the hypothalamic-pituitary axis and use of somatostatin receptor ligands and dopamine agonists in Cushing Disease

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
General Endocrinology
Neuroendocrinology and Pituitary
Surgery
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
08/20/2014
Course expires: 
09/30/2016
Event starts: 
09/04/2014 - 9:15pm
Event ends: 
09/04/2014 - 11:15pm
Rating: 
5
Hilton San Francisco Union Square
333 O'Farrell Street
San Francisco, CA 94102
United States

Maria Fleseriu, MD, FACE – Program Director
Associate Professor of Medicine (Endocrinology) & Neurosurgery
Director of the Northwest Pituitary Center
Oregon Health and Science University
Portland, Oregon

Lewis Blevins Jr, MD
Clinical Professor of Neurological Surgery and Medicine
Medical Director, California Center for Pituitary Disorders at UCSF
University of California, San Francisco
San Francisco, California

Daniel F Kelly, MD
Director, Brain Tumor Center
John Wayne Cancer Institute at Saint John’s Health Center
Santa Monica, California

Peter J Trainer, MD, FRCP
Professor of Endocrinology
The Christie NHS Foundation Trust
Manchester, United Kingdom 

Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved and/or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Maria Fleseriu, MD. FACE: Advisory Board Member and Principal Investigator, Novartis Pharmaceuticals; Principal Investigator, Cortendo

Daniel F Kelly, MD: Royalties, Mizuho, Inc.  

Peter J Trainer, MD, FRCP: Principal Investigator, HRA Pharma

The following faculty reported no relevant financial relationships: Lewis Blevins Jr, MD  

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:

Andrea L. Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC Committee members reported relevant financial relationships:

Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.

Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk

Irl B Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi

E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;

Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche

Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation

Accreditation Period

Course opens: 
08/20/2014
Course expires: 
09/30/2016